Madrigal Pharmaceuticals presents five health economics outcomes abstracts

Madrigal Pharmaceuticals announced five health economics abstracts being presented at the NASH-TAG Conference, taking place from January 4-6, 2024 in Park City, Utah. A summary of the health economics outcomes research abstracts being presented at NASH-TAG follows: Abstract #21: “Non-invasive tests as a prediction tool to assess MASH resolution score.” In an evaluation of biopsy and noninvasive test data from patients included in the TARGET-NASH registry, the FibroScan-AST score, FibroScan vibration-controlled transient elastography, and the aspartate aminotransferase-to-platelet ratio index demonstrated a strong ability to predict NASH resolution. Overall, patients without NASH resolution had larger baseline median FIB-4, APRI and VCTE scores. Abstract #25: “Characterizing the management of patients with NASH in real-world clinical practice – Low utilization of gastroenterology and hepatology specialty care.” In a review of patient records from an Optum database, researchers found that a substantial proportion of patients with NASH were not assessed by a gastroenterologist or hepatologist at the frequency recommended in medical guidelines, even when diagnosed with cirrhosis. Among patients with cirrhosis, greater than or equal to25% were not seen by a specialist at the recommended frequency of once per year. Among those without cirrhosis, greater than or equal to50% were not assessed by a specialist at the recommended frequency of every 2-3 years. Abstract #26: “Characterizing the real-world clinical outcomes of patients with NASH without cirrhosis versus with cirrhosis.” In another review of patient records from an Optum database, researchers examined the relationship between NASH disease progression and risk of clinical outcomes. For patients with NASH without cirrhosis at baseline, the risk of experiencing all-cause death, progression to cirrhosis or decompensated cirrhosis, or a liver transplant increased from 10.5% in year one to 31.4% by year five. Abstract #27: “A longitudinal assessment of cardiovascular risk for patients enrolled in TARGET-NASH.” In an analysis of patient data from the TARGET-NASH registry, patients with NASH with cirrhosis were found to be at an increased risk of cardiovascular events compared to patients with noncirrhotic NASH, even after adjusting for traditional cardiovascular risk factors. Abstract #41: “Enhancing ASCVD Risk Prediction in NASH/NAFLD Patients.” In an analysis of a retrospective dataset from a large U.S. integrated delivery network health system, researchers compared observed events to a model that predicted events and found that a cardiovascular risk model that included liver-specific biomarkers improved the prediction of cardiovascular mortality and myocardial infarction events in patients with NASH relative to the American Heart Association’s Atherosclerotic Cardiovascular Disease Risk Estimator Plus.